Our goal is to target novel immune-modulating agents directly to the pancreatic tumor site using a tumorspecificMUC1 antibody as a carrier. This will be administered in combination with the MUC1/KRAS peptidevaccine and low-dose gemcitabine. MUC1 and Kras are over expressed in 90% of pancreatic ductaladenocarcinomas (PDA) and have long been targets for therapeutic interventions. Thus far, cancer vaccineshave not been clinically as successful as one had hoped for. Vaccines have failed to generate long-termimmune memory against the tumor antigens because tumors have adopted ways to escape immunerecognition and killing. Several new agents that can reverse immune evasion have been tested with modestclinical responses probably because the agents were administered systemically and may have neverreached the tumor site. We hypothesize that by directly delivering the immune modulating agents to thepancreatic tumor site and combining this with a multi-peptide MUC1/Kras vaccine, we can generate a robustanti-tumor response with a strong memory response. The treatment will affect both localized anddisseminated tumors, and strong memory responses will prevent recurrence. We will test the hypothesis inan appropriate mouse model of spontaneous PDA that clearly resembles the human disease.
Our specificaims are: 1) To optimize a MUC1/Kras-based vaccine in the PDA X MUCLTg mice by immobilizing fourimmune modulating agents directly to the tumor site by chemically conjugating the agents to a tumor-specificMUC1 monoclonal antibody. This antibody will home not only to the primary pancreas tumor but also to themetastatic tumor sites that over express MUC1; 2) To assess immune status and naturally occurring MUC1 -specific cellular and humoral immune responses in pancreatic cancer patients.
This aim will provide a soliddatabase as to the roles of tumor-associated tolerizing factors and anti-MUCI responses in tumorprogression, metastasis, survival, and prognosis and 3) A Phase I trial for the treatment of pancreas cancer.This trial utilizes a MUC1-pep1ide based vaccine, celecoxib, gemcitabine, and external beam radiation inpatients with locally advanced pancreatic cancer. We will monitor the immune tolerance mechanisms, andthe immune responses before, during, and after treatment. Future: This study could lead to development of anew combination modality for the treatment of localized and disseminated pancreas tumors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA102701-06
Application #
7510798
Study Section
Special Emphasis Panel (ZCA1-GRB-I (M1))
Project Start
2008-07-01
Project End
2013-06-30
Budget Start
2008-07-01
Budget End
2009-08-31
Support Year
6
Fiscal Year
2008
Total Cost
$303,584
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Nagpal, Sajan Jiv Singh; Bamlet, William R; Kudva, Yogish C et al. (2018) Comparison of Fasting Human Pancreatic Polypeptide Levels Among Patients With Pancreatic Ductal Adenocarcinoma, Chronic Pancreatitis, and Type 2 Diabetes Mellitus. Pancreas 47:738-741
Wolf, Susan M; Scholtes, Emily; Koenig, Barbara A et al. (2018) Pragmatic Tools for Sharing Genomic Research Results with the Relatives of Living and Deceased Research Participants. J Law Med Ethics 46:87-109
Tamura, Koji; Yu, Jun; Hata, Tatsuo et al. (2018) Mutations in the pancreatic secretory enzymes CPA1 and CPB1 are associated with pancreatic cancer. Proc Natl Acad Sci U S A 115:4767-4772
Chaffee, Kari G; Oberg, Ann L; McWilliams, Robert R et al. (2018) Prevalence of germ-line mutations in cancer genes among pancreatic cancer patients with a positive family history. Genet Med 20:119-127
Shroff, Rachna T; Hendifar, Andrew; McWilliams, Robert R et al. (2018) Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation. JCO Precis Oncol 2018:
McWilliams, Robert R; Wieben, Eric D; Chaffee, Kari G et al. (2018) CDKN2A Germline Rare Coding Variants and Risk of Pancreatic Cancer in Minority Populations. Cancer Epidemiol Biomarkers Prev 27:1364-1370
Supekar, Nitin T; Lakshminarayanan, Vani; Capicciotti, Chantelle J et al. (2018) Synthesis and Immunological Evaluation of a Multicomponent Cancer Vaccine Candidate Containing a Long MUC1 Glycopeptide. Chembiochem 19:121-125
Cohen, Joshua D; Li, Lu; Wang, Yuxuan et al. (2018) Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science 359:926-930
Zhang, Mingfeng; Lykke-Andersen, Soren; Zhu, Bin et al. (2018) Characterising cis-regulatory variation in the transcriptome of histologically normal and tumour-derived pancreatic tissues. Gut 67:521-533
Kanamori, Karina S; de Oliveira, Guilherme C; Auxiliadora-Martins, Maria et al. (2018) Two Different Methods of Quantification of Oxidized Nicotinamide Adenine Dinucleotide (NAD+) and Reduced Nicotinamide Adenine Dinucleotide (NADH) Intracellular Levels: Enzymatic Coupled Cycling Assay and Ultra-performance Liquid Chromatography (UPLC)-Mass Bio Protoc 8:

Showing the most recent 10 out of 336 publications